A mouse anti-human cd123 monoclonal antibody and its application

A monoclonal antibody, mouse anti-human technology, applied in the field of immunology, can solve the problems that CD123 antibody does not achieve the expected therapeutic effect and is not suitable for clinical treatment, etc., and achieve the effect of strong binding specificity

Active Publication Date: 2022-08-02
INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And some CD123 antibodies did not achieve the expected therapeutic effect
For example, 7G3 and radionuclides 111 The indium-conjugated drug CSL360, in the phase I clinical trial of 40 patients with relapsed, drug-resistant and high-risk AML, only 2 patients responded to the treatment, indicating that CSL360 is ineffective for most patients and is not suitable for clinical use treat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A mouse anti-human cd123 monoclonal antibody and its application
  • A mouse anti-human cd123 monoclonal antibody and its application
  • A mouse anti-human cd123 monoclonal antibody and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0049] The present invention will be further described below with reference to specific embodiments, but the protection scope of the present invention is not limited.

[0050] 1. Mouse Hybridoma Monoclonal Antibody Screening

[0051] The 3T3 cells transfected with lentivirus and stably expressing human CD123 protein on the cell membrane were used as the immunogen. IL3RA (encoding human CD123 protein) was constructed. Balb / c mice were immunized by intraperitoneal injection, 1×10 7 3T3 / CD123 + Cells / time, booster immunization was performed on the 3rd and 5th weeks after the primary immunization, respectively, and the mouse tail blood was collected on the 8th day after the booster immunization. Serum, diluted in PBS to different concentrations: 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800. Collect 3T3, 3T3 / CD123 + Cells, washed once with PBS, and counted with 1 × 10 cells per sample 6 100 μl of serum at different dilutions were added to the cells. In the negative co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
aggregationaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a mouse anti-human CD123 monoclonal antibody and application thereof, comprising a heavy chain variable region sequence and a light chain variable region sequence; the CDR region of the heavy chain variable region sequence comprises three sequences as follows, respectively As shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3; the CDR region of the light chain variable region sequence comprises three following sequences, respectively as SEQ ID NO: 4, SEQ ID NO : 5, shown in SEQ ID NO: 6. The anti-CD123 monoclonal antibody 13C3 provided by the present invention can not only be used to detect cells expressing human CD123, but also can be used alone or in combination with other methods in tumor immunotherapy targeting human CD123 protein, that is, it can be effectively used in the treatment of tumors, infections In the preparation of drugs for sexually transmitted diseases, autoimmune diseases and anti-immune rejection.

Description

technical field [0001] The invention relates to the technical field of immunology, in particular to a mouse anti-human CD123 monoclonal antibody and its application. Background technique [0002] Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal proliferation of primitive and immature myeloid cells in the bone marrow and peripheral blood. Most of the current treatments for AML have poor prognosis, and patients who have achieved complete remission with conventional chemotherapeutic drugs will still face problems such as relapse and drug resistance. [0003] Recent studies have found that leukemia stem cells (LSCs) are the origin of malignant cell populations in AML. Like normal stem cells, LSCs have the ability to proliferate and self-renew indefinitely. Their self-protection mechanism and protective microenvironment make conventional chemotherapeutic drugs ineffective. Residual LSCs are considered to be the cause of AML development, drug r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N5/20C12N15/13G01N33/68G01N33/577A61K39/395A61P35/00A61P31/00A61P37/02A61P37/06C12R1/91
Inventor 熊冬生卢杨范冬梅王建祥张砚君叶舟张益枝杨纯正
Owner INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap